TY - JOUR T1 - GRAPPA Treatment Recommendations: 2021 Update JF - The Journal of Rheumatology JO - J Rheumatol SP - 52 LP - 54 DO - 10.3899/jrheum.211331 VL - 49 IS - 6 Suppl 1 AU - Laura C. Coates AU - Nadia Corp AU - Danielle A. van der Windt AU - Denis O’Sullivan AU - Enrique R. Soriano AU - Arthur Kavanaugh Y1 - 2022/06/01 UR - http://www.jrheum.org/content/49/6_Suppl_1/52.abstract N2 - Since its inception, one of the central missions of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has been the development of treatment recommendations for patients with psoriatic arthritis (PsA). The initial guidelines, developed in 2009, were updated in 2015. Because of the abundance of new data concerning the therapeutic approach to PsA, GRAPPA members have been working throughout 2020–2021 to once again update the recommendations. At the GRAPPA 2021 annual meeting, the full committee presented proposals from each of the treatment domain groups, including the comorbidities and related conditions groups, based on previous systematic literature reviews. Overarching principles and summary evidence tables were presented, including results from a GRAPPA membership survey of patients and clinicians to assess levels of agreement. A draft of the figure for the treatment recommendations was presented and discussed with the wider membership. ER -